• Sibel Health

  Led · Series C · Mar 2025

  Founded in 2018, Chicago-based Sibel Health offers the ANNE® platform, a suite of FDA-cleared wearable sensors integrated with mobile software, cloud analytics, and AI-driven algorithms to capture continuous, real-world vital-sign data. The system is already paired with Samsung mobile devices for waveform display and alerting and is used by leading pharmaceutical companies through the Discovery platform to collect home-based data for clinical trials. Sibel aims to move healthcare from episodic, reactive monitoring to continuous, predictive clinical intelligence. Recent strategic collaborations with Maruho focus on dermatology-related digital therapeutics, starting with an itch-monitoring application. The company maintains an international presence with an office in Seoul and touts a mission of delivering “Better Health Data for All®.” Financially, Sibel has brought its total Series C funding to $39 million, supported by a mix of healthcare, strategic, and technology investors. Two new board appointments—Kimberly Querrey as Chairwoman and Tim Sullivan as an independent director—add governance and healthcare commercialization expertise to guide upcoming growth.

• Epicore Biosystems

  Led · Series B · Feb 2025

  Epicore Biosystems develops sweat-sensing wearables and cloud analytics that provide real-time, personalized hydration and health insights. The company was spun out of Northwestern University’s Querrey Simpson Institute for Bioelectronics and the John Rogers Laboratory and is led by CEO Dr. Roozbeh Ghaffari. Its clinically validated biowearable solutions and cloud analytics are deployed globally and licensed by Fortune 1000 companies, the Department of Defense, and the National Institute of Health. Epicore raised an additional $6M in Series B funding, bringing the total Series B to $32M after an initial $26M tranche led by the Steele Foundation for Hope. The company intends to use the funds to expand its Connected Hydration solution into industrial markets in Australia, the Middle East and Asia, scale real-time cloud analytics with personalized hydration guidance, and validate new biomarkers for kidney health and stress management. Backers in the new tranche included Alumni Ventures and Joyance Partners. Epicore Biosystems is a Cambridge, MA–based digital health company that builds advanced sweat-sensing wearables and a connected cloud analytics platform. Its product suite includes the Gx Sweat Patch (commercialized with PepsiCo and Gatorade), the Discovery Patch® Sweat Collection System (an FDA Class I device), and the Connected Hydration wearable and cloud platform tailored for industrial workers. The company’s clinically validated biowearable solutions and analytics are deployed globally and licensed by Fortune 500 companies, the Department of Defense, and the National Institutes of Health. Led by CEO Dr. Roozbeh Ghaffari, Epicore was spun out of Northwestern University’s Querrey Simpson Institute for Bioelectronics and the John Rogers Laboratory. The company raised $26M in a Series B and intends to use the funds to drive global adoption of its personalized hydration and cloud analytics platform. Epicore plans to expand into new biomarker targets relevant to kidney health, women’s health, malnutrition, and environmental toxin exposures. Epicore Biosystems develops clinically validated biowearable products and cloud analytics that deliver real-time personalized insights for hydration, stress and wellness. Its flagship Connected Hydration solution comprises a flexible wearable patch, a mobile application and a cloud analytics engine. The wearable patch has an extended battery life of over 1,000 hours and never requires charging. Epicore’s products and analytics are deployed globally and are licensed by Fortune 500 companies, the Department of Defense and the National Institutes of Health. Led by CEO Dr. Roozbeh Ghaffari, the company says it will use new funding to expand access to personalized hydration insights by scaling Connected Hydration across Japan and Asia. The company is based in Cambridge, MA.

• Rhaeos

  Led · Series A · Feb 2023

  Rhaeos is a clinical-stage medical device company focused on addressing unmet needs in the care of people with hydrocephalus and developing wearable sensors for chronic conditions. Its core product, the FlowSense shunt monitor, is a wireless, non-invasive thermal sensor delivered as a small, bandage-sized patch that adheres above implanted shunt tubing. FlowSense rapidly monitors shunt function and wirelessly transmits critical data to a mobile app in minutes to support clinical decision making. Rhaeos received FDA Breakthrough Device Designation for FlowSense in 2020 and is currently evaluating the device in a multi-center FDA pivotal study in the US. The company intends to use the Series A proceeds to support an in-hospital launch of FlowSense and anticipates making the monitor commercially available to physicians and patients in 2023. The company is led by CEO Anna Lisa Somera. Rhaeos is a private, clinical-stage medical device company based in Evanston, Ill., formed out of the John A. Rogers Research Group at Northwestern University. The company is developing FlowSense™, a noninvasive wireless wearable sensor that addresses a clinical unmet need for patients with hydrocephalus and is initially targeted at the neurosurgical suite. Rhaeos has received support from federal and nonprofit sources, including the National Institutes of Health and the National Science Foundation, as well as foundations and pediatric device consortia. The company closed a $2.2M seed financing and has secured more than $8M in total dilutive and non-dilutive financing to date. Proceeds from the seed round will be used to prepare for the 2022 commercial launch of FlowSense. Additional institutional and accelerator supporters include MedTech Innovator and several pediatric device accelerators and consortiums.

• Zenysis

  Led · Series B · Jun 2022

  Zenysis provides a data-integration and decision-support platform (including an open-source offering called Harmony) that aggregates fragmented data from multiple government agencies, UN agencies and NGOs into a single real-time control room. Its software is used by governments and partners in nine countries across Africa, South America and Asia, and has supported responses such as Mozambique’s 2019 cholera vaccination campaign. The company measures traction by the number of health priorities its software supports, including HIV, tuberculosis, childhood vaccination, maternal and child health, family health and COVID. Zenysis was founded in 2016 and is headquartered in San Francisco and Cape Town. With the new financing it plans to expand its range of health programs into adjacent verticals, invest in strategic partnerships and help governments tackle the intersection of climate change and human health. Management also plans to triple the company’s geographical footprint over the next two years with a significant focus on expanding across Africa.

No current team members are available.